Claims for Patent: 10,143,752

✉ Email this page to a colleague

Summary for Patent: 10,143,752

Title:	Methods of treating ulcerative colitis
Abstract:	Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human .alpha.4.beta.7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo.
Inventor(s):	Fox; Irving H. (Wellesley, MA), Scholz; Catherine (Woburn, MA)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/214,993
Patent Claims:	1. A method for achieving mucosal healing and maintaining clinical remission in a human patient having moderately to severely active ulcerative colitis, comprising intravenously administering a clinically proven effective dose of 300 mg of an antibody that has binding specificity for human .alpha.4.beta.7 integrin every eight weeks, wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4, and wherein mucosal healing is achieved and clinical remission is maintained, and mucosal healing is defined as an endoscopic subscore of 1 point or less. 2. The method of claim 1, wherein the heavy chain of the antibody comprises amino acids 20 to 470 of SEQ ID NO:2, and the light chain of the antibody comprises amino acids 20 to 238 of SEQ ID NO:4. 3. The method of claim 1, wherein each dose is intravenously administered as an infusion over about 30 minutes. 4. The method of claim 1, wherein the human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNF.alpha. antagonist. 5. A method for achieving mucosal healing and maintaining clinical remission in a human patient having moderately to severely active ulcerative colitis, comprising intravenously administering a clinically proven effective dose of 300 mg of vedolizumab every eight weeks, wherein mucosal healing is achieved and clinical remission is maintained, and mucosal healing is defined as an endoscopic subscore of 1 point or less.

Details for Patent 10,143,752

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	May 20, 2014	⤷ Subscribe	2031-05-02
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	Injection	761133	September 27, 2023	⤷ Subscribe	2031-05-02
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133	September 27, 2023	⤷ Subscribe	2031-05-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.